# Neo-Healer (anbenitamab): what clinicians are saying

> 104 statements from 22 sources (3 videos, 18 posts, 1 paper), 13 of them from 7 confirmed clinicians, each linked to its source. Commentary checked Nov 20, 2026.

## Report

- Trial: A Randomized, Controlled, Open-label, Multicenter, Phase III Clinical Trial to Compare the Efficacy and Safety of KN026 Combined With HB1801 ± Carboplatin Versus Trastuzumab Combined With Pertuzumab and Docetaxel ± Carboplatin in Neoadjuvant Treatment of Early or Locally Advanced HER2-positive Breast Cancer.
- NCT ID: NCT06747338
- Registry: https://clinicaltrials.gov/study/NCT06747338
- Sponsor: Shanghai JMT-Bio Inc.
- Phase: Phase 3
- Status: Active, not recruiting
- Drugs tested: anbenitamab plus HB1801
- Indication: early or locally advanced HER2-positive breast cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-11-20 UTC
- Last checked: 2026-11-20 UTC
- Release hash: f1f08e42df26e2c2ed6bb58ce7e7fc941a0b89ca6050a9d2498b4880318dd7f9

## Counts

- Commentary sources screened: 43
- Sources cited by verified statements: 22
- Verified statements: 104
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 13
- Findings: 10
- Named people in screened sources (unnamed speakers and accounts not counted): 16
- Speakers cited: 16
- Cited speakers with a verified identity: 15
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 7
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 7
- By role and specialty (the abstract's specialty counts):
  - 6 physician, Medical oncology
  - 1 physician, specialty not confirmed
- Organisational or shared accounts (not counted as people): 4

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

A medical oncologist thinks Neo-Healer could change treatment because of its response gain, but still awaits survival results. Another speaker sees potential for use in Asia while seeking evidence of applicability to other ethnicities. Medical oncologists question how much of the gain reflects HER2 blockade rather than nab-docetaxel; one also requires independent development and Western validation before adoption.

## Question clinicians left open

What do clinicians say they need to see on EFS/OS, the contribution of different taxanes and Western validation before considering neoadjuvant anbenitamab plus HB1801, with or without carboplatin, a new standard for stage II–III HER2-positive breast cancer?

From finding F1 (22 statements from 10 speakers in 14 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Neo-Healer: some speakers want more data; some see practice-change potential
  - 22 statements from 10 speakers in 14 sources, 1 of them a podcast or video.
  - 5 of the 10 named speakers in this finding hold this view; 3 of the 10 hold its caveat, “some see practice-change potential”.
  - 4 of the report's 7 cited clinicians.
- F2. HER2 targeting: most speakers question attribution; some clinicians see possible gains
  - 22 statements from 7 speakers in 11 sources, 2 of them podcasts or videos.
  - 6 of the 7 named speakers in this finding hold this view; 2 of them hold its caveat, “some clinicians see possible gains”.
  - 6 of the report's 7 cited clinicians.
- F3. Carboplatin: what speakers say
  - 15 statements from 3 speakers in 5 sources, 1 of them a podcast or video.
  - No named clinician · accounts and unnamed speakers.
- F4. Neo-Healer: most speakers cite AE rates; one weighs a shorter non-ADC course
  - 11 statements from 5 speakers in 7 sources, 1 of them a podcast or video.
  - 4 of the 5 named speakers in this finding hold this view; 1 of the 5 holds its caveat, “one weighs a shorter non-ADC course”.
  - 2 of the report's 7 cited clinicians.
- F5. Neo-Healer/DB11: what speakers say
  - 9 statements from 2 speakers in 4 sources, 1 of them a podcast or video.
  - No named clinician · accounts and unnamed speakers.
- F6. Beyond China: some speakers seek validation; one questions Western access
  - 12 statements from 4 speakers in 9 sources, 2 of them podcasts or videos.
  - 2 of the 4 named speakers in this finding hold this view; 1 of the 4 holds its caveat, “one questions Western access”.
  - 1 of the report's 7 cited clinicians.
- F7. Payload-free backbone: a speaker asks if it could reserve T-DXd for residual disease
  - 4 statements from 1 speaker in 2 sources.
  - The one named speaker in this finding holds this view.
  - No named clinician · accounts and unnamed speakers.
- F8. Regimen: a speaker risk-adapts; one wants long-term T-DXd data
  - 10 statements in 1 source, a podcast or video.
  - No named speaker is counted in this finding: its title's view comes from speakers the source does not name.
  - No named clinician · accounts and unnamed speakers.

### Beyond the trial population

- F9. T-DXd×4: a speaker awaits RFS/OS; one leans on other evidence
  - 8 statements in 1 source, a podcast or video.
  - No named speaker is counted in this finding: its title's view comes from speakers the source does not name.
  - No named clinician · accounts and unnamed speakers.
- F10. Neo-Healer: a clinician sees a possible GI preview; one notes HER2 advances
  - 2 statements from 1 speaker in 2 sources, 1 of them a podcast or video.
  - The one named speaker in this finding holds this view, a confirmed clinician; 1 of the 1 holds its caveat, “one notes HER2 advances”.
  - 1 of the report's 7 cited clinicians.

2 of the 10 findings and 7 of the 104 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 22 | 21 | 14 | 10 | 4 |
| F2 | 22 | 34 | 11 | 7 | 3 |
| F3 | 15 | 21 | 5 | 3 | 2 |
| F4 | 11 | 11 | 7 | 5 | 3 |
| F5 | 9 | 13 | 4 | 2 | 4 |
| F6 | 12 | 13 | 9 | 4 | 4 |
| F7 | 4 | 2 | 2 | 1 | 3 |
| F8 | 10 | 16 | 1 | 0 | 3 |
| F9 | 8 | 11 | 1 | 0 | 3 |
| F10 | 2 | 2 | 2 | 1 | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 13 | 2 | 0 | 0 | 7 | 25 | 3 | 12 posts and articles, 1 podcast or video, 1 publication |
| F2 | 11 | 3 | 0 | 3 | 5 | 37 | 12 | 8 posts and articles, 2 podcasts and video, 1 publication |
| F3 | 10 | 2 | 0 | 0 | 3 | 24 | 12 | 3 posts and articles, 1 podcast or video, 1 publication |
| F4 | 5 | 0 | 0 | 1 | 5 | 13 | 2 | 5 posts and articles, 1 podcast or video, 1 publication |
| F5 | 2 | 1 | 0 | 5 | 1 | 15 | 5 | 2 posts and articles, 1 podcast or video, 1 publication |
| F6 | 4 | 5 | 0 | 0 | 3 | 13 | 3 | 6 posts and articles, 2 podcasts and video, 1 publication |
| F7 | 1 | 1 | 0 | 0 | 2 | 4 | 0 | 1 post or article, 1 publication |
| F8 | 6 | 2 | 0 | 0 | 2 | 16 | 14 | 1 podcast or video |
| F9 | 4 | 3 | 0 | 0 | 1 | 12 | 8 | 1 podcast or video |
| F10 | 2 | 0 | 0 | 0 | 0 | 2 | 1 | 1 post or article, 1 podcast or video |

### Trial dimensions

- Primary endpoint: tpCR (BIRC, AJCC 8th): F1 (9 shared claims), F2 (5 shared claims), F3 (3 shared claims), F4 (3 shared claims)
- Secondary endpoints: F1 (8 shared claims), F2 (2 shared claims), F4 (2 shared claims), F6 (3 shared claims)
- Population and setting: F1 (5 shared claims), F2 (2 shared claims), F3 (3 shared claims), F4 (2 shared claims), F5 (2 shared claims), F6 (5 shared claims), F8 (3 shared claims)
- The comparison: F1 (1 shared claims), F2 (16 shared claims), F3 (1 shared claims), F4 (3 shared claims), F5 (7 shared claims), F6 (3 shared claims)
- Safety and tolerability: F1 (3 shared claims), F2 (2 shared claims), F3 (1 shared claims), F4 (8 shared claims), F5 (1 shared claims)
- Design and conduct: F2 (7 shared claims), F3 (2 shared claims), F6 (5 shared claims)

## Abbreviations

- AE: adverse event
- EFS: event-free survival
- GI: gastrointestinal
- HCP: healthcare professional
- HER2: human epidermal growth factor receptor 2
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- OS: overall survival
- RFS: relapse-free survival
- T-DXd: trastuzumab deruxtecan

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 10 | Titles free |
| Detailed analysis | 12 sections | Paid |
| Verified statements with short source quotes and links | 104 | Paid |
| Who said each statement: the cited speakers | 16 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 7 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 15 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 11 | Free |
| Sources with links | 22 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 7 of the 16 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

11 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: tpCR (BIRC, AJCC 8th) | discussed | 20 | 15 |
| Secondary endpoints | discussed | 10 | 7 |
| Population and setting | discussed | 16 | 9 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 29 | 12 |
| Safety and tolerability | discussed | 9 | 7 |
| Design and conduct | discussed | 12 | 7 |
| Mechanistic promise and component attribution | discussed | 14 | 7 |
| Carboplatin omission and individualized use | discussed | 14 | 4 |
| Reception, adoption thresholds and access | discussed | 24 | 17 |
| DESTINY-Breast11 comparisons and residual-disease strategy | discussed | 22 | 3 |
| Wider HER2 development perspective | discussed | 2 | 2 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 44 statements · 42%** | | | |
| YouTube | 44 | 3 | 4 |
| **Posts · 39 statements · 38%** | | | |
| X threads | 32 | 16 | 36 |
| LinkedIn posts | 7 | 2 | 2 |
| Bluesky threads | 0 | 0 | 1 |
| **Primary sources · 21 statements · 20%** (cited for context, not screened) | | | |
| Publications (primary source, cited for context) | 21 | 1 | not screened |

- Screened window: 2026-04-01 to 2026-11-05
- Cited window: 2026-04-01 to 2026-11-05
- Retrieved: 2026-11-20

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Randomized, Controlled, Open-label, Multicenter, Phase III Clinical Trial to Compare the Efficacy and Safety of KN026 Combined With HB1801 ± Carboplatin Versus Trastuzumab Combined With Pertuzumab and Docetaxel ± Carboplatin in Neoadjuvant Treatment of Early or Locally Advanced HER2-positive Breast Cancer.
- Registry: NCT06747338 (https://clinicaltrials.gov/study/NCT06747338)
- Study IDs: KN026-004
- Sponsor: Shanghai JMT-Bio Inc.
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 520 (estimated)
- Start: 2024-12-16 (actual)
- Primary completion: 2026-12-16 (estimated)
- Primary endpoint: tpCR (BIRC, AJCC 8th) (Through study completion, an average of 1 year)
- Intervention: KN026 (drug)
- Intervention: HB1801 (drug)
- Intervention: Pertuzumab (drug)
- Intervention: Trastuzumab (drug)
- Intervention: Docetaxel (drug)
- Intervention: Carboplatin (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 1 matching source (1 X thread) could not be read and is not included.
- 43 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 18 sources about other trials or topics are not included.
- The sources reviewed do not establish the prevalence of any view among HCPs, and source counts or reposts cannot be treated as independent clinician endorsement.
- Several video statements cannot be assigned to a named speaker. Publisher participant lists and professional profiles do not establish who made those statements.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Relevant discussion may be missing when it never names the trial, uses unexpected spelling or addresses the same treatment decision without recognizable study terminology. One additional X conversation could not be assessed.
- No separate protocol was available. The regulatory material reviewed was incomplete, and no exact KN026 or HB1801 label was located; the report does not establish comprehensive approval or availability status.
- Early endpoint-announcement reactions, later numerical-result commentary and subsequent panel recollections have different information contexts. Their dates do not establish a change of mind.
- Cross-study pCR and toxicity comparisons do not establish comparative superiority. The sources’ population, comparator and exposure-duration qualifications remain essential.
- The unexplained negative reply and the unspecified questions relayed from a discussant cannot support more specific objections than the text provides.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-20 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-20 UTC. No changes.

## Offer

- Size: Focused · 104 verified statements · 13 from 7 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (15 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/neo-healer-nct06747338
- Agents: POST https://www.erudio.com/api/orders with {"report": "neo-healer-nct06747338", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=neo-healer-nct06747338

## Cite

Erudio Health. Neo-Healer (NCT06747338): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 20, 2026. https://www.erudio.com/reports/neo-healer-nct06747338

## Questions

### How much does the Neo-Healer report cost?

One edition costs $750 (Focused · 104 verified statements · 13 from 7 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the Neo-Healer report cover?

104 statements from 22 sources (3 videos, 18 posts, 1 paper), 13 of them from 7 confirmed clinicians, each linked to its source. Commentary checked Nov 20, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the Neo-Healer report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "neo-healer-nct06747338" }) previews it and create_order({ "report": "neo-healer-nct06747338", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the Neo-Healer report?

Edition 1 (version 1.0.0), accepted Nov 20, 2026 UTC; last checked for new commentary Nov 20, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/neo-healer-nct06747338.json
- Markdown: https://www.erudio.com/reports/neo-healer-nct06747338.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/neo-healer-nct06747338/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "neo-healer-nct06747338"}`
